Correlation Between Nephros and Elite Pharma
Can any of the company-specific risk be diversified away by investing in both Nephros and Elite Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nephros and Elite Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Nephros and Elite Pharma, you can compare the effects of market volatilities on Nephros and Elite Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nephros with a short position of Elite Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nephros and Elite Pharma.
Diversification Opportunities for Nephros and Elite Pharma
-0.41 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Nephros and Elite is -0.41. Overlapping area represents the amount of risk that can be diversified away by holding Nephros and Elite Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Elite Pharma and Nephros is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nephros are associated (or correlated) with Elite Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Elite Pharma has no effect on the direction of Nephros i.e., Nephros and Elite Pharma go up and down completely randomly.
Pair Corralation between Nephros and Elite Pharma
If you would invest 3.73 in Elite Pharma on September 1, 2024 and sell it today you would earn a total of 0.00 from holding Elite Pharma or generate 0.0% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 0.79% |
| Values | Daily Returns |
Nephros vs. Elite Pharma
Performance |
| Timeline |
| Nephros |
| Elite Pharma |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Nephros and Elite Pharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Nephros and Elite Pharma
The main advantage of trading using opposite Nephros and Elite Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nephros position performs unexpectedly, Elite Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Elite Pharma will offset losses from the drop in Elite Pharma's long position.| Nephros vs. Precision Optics, | Nephros vs. Repro Med Systems | Nephros vs. InfuSystems Holdings | Nephros vs. Utah Medical Products |
| Elite Pharma vs. Amarantus Bioscience Holdings | Elite Pharma vs. Intelgenx Technologs | Elite Pharma vs. Cytosorbents Crp |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Complementary Tools
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |